{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T20:37:15Z","timestamp":1794256635536,"version":"4.9.0"},"reference-count":22,"publisher":"BMJ","issue":"12","license":[{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"unspecified","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"crossref","award":["JP21lk0201131"],"award-info":[{"award-number":["JP21lk0201131"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"crossref","award":["JP22lk0201162"],"award-info":[{"award-number":["JP22lk0201162"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,12,5]]},"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Accumulating evidence suggests that glucagon-like peptide-1 (GLP-1) receptor agonists may have therapeutic effects against Parkinson\u2019s disease (PD); however, clinical evidence has not yet been established and remains controversial. This clinical study aims to assess the efficacy, disease-modifying effects, safety and optimal dose of oral semaglutide tablets, a GLP-1 receptor agonist, in idiopathic patients with PD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>The MOST-ABLE study is a phase 2, multicentre, double-blind, randomised, placebo-controlled trial of oral semaglutide tablets in 99 participants with PD. Patients with PD (Hoehn &amp; Yahr stages 1\u20132.5) at eight sites in Japan will be randomly assigned in a 1:1:1 ratio to one of three groups: oral semaglutide tablets (7\u2009mg or 14\u2009mg) or placebo. The study drugs will be administered once daily as an add-on to conventional medical treatment for PD. After 36 weeks of treatment, the participants will be treated without the study drugs for 12 weeks. The efficacy outcomes include Movement Disorder Society-Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS), Parkinson\u2019s Disease Questionnaire-39, cognitive tests and dopamine transporter imaging. The primary endpoint is the change in the MDS-UPDRS part 3 score in the practically defined off-medication state from baseline at 48 weeks between the treatment allocation groups. The safety and tolerability will also be evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The study protocol was approved by the Pharmaceuticals and Medical Devices Agency of Japan and the study was approved by the institutional review boards at the University of Osaka Hospital and each study site. All participants are required to provide informed consent. The results will be disseminated in peer-reviewed journals, presented at scientific meetings and presented to patients in a lay summary format.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      jRCT2051230090 (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/jrct.mhlw.go.jp\/latest-detail\/jRCT2051230090\">https:\/\/jrct.mhlw.go.jp\/latest-detail\/jRCT2051230090<\/jats:ext-link>\n                      ), universal trial number U1111-1271-3794.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-112318","type":"journal-article","created":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T06:10:32Z","timestamp":1766643032000},"page":"e112318","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Disease-modifying effect, safety and optimal dose of oral semaglutide tablets for patients with Parkinson\u2019s disease (MOST-ABLE study): protocol for a randomised, double-blind, placebo-controlled study"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9147-8058","authenticated-orcid":false,"given":"Yasuyoshi","family":"Kimura","sequence":"first","affiliation":[{"name":"Department of Neurology, The University of Osaka Graduate School of Medicine, Suita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Koda","sequence":"additional","affiliation":[{"name":"Department of Medical Innovation, The University of Osaka Hospital, Suita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Kurakami","sequence":"additional","affiliation":[{"name":"Institute for Clinical and Translational Science, Nara Medical University, Kashihara, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1818-2194","authenticated-orcid":false,"given":"Shigeru","family":"Sakamoto","sequence":"additional","affiliation":[{"name":"Department of Medical Innovation, The University of Osaka Hospital, Suita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Iwasaki","sequence":"additional","affiliation":[{"name":"Department of Medical Innovation, The University of Osaka Hospital, Suita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanako","family":"Asai","sequence":"additional","affiliation":[{"name":"Department of Neurology, The University of Osaka Graduate School of Medicine, Suita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindun","family":"Ge","sequence":"additional","affiliation":[{"name":"Department of Neurology, The University of Osaka Graduate School of Medicine, Suita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Advanced Radioisotope Medicine, Institute for Radiation Sciences, The University of Osaka, Suita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Tsuboi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyuki","family":"Matsukawa","sequence":"additional","affiliation":[{"name":"Department of Neurology and Neuroscience, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Kano","sequence":"additional","affiliation":[{"name":"Department of Neurology, Toho University Faculty of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Matsuse","sequence":"additional","affiliation":[{"name":"Department of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan"},{"name":"Department of Neurology, Kyushu University Hospital, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Tomiyama","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hirosaki University School of Medicine, Hirosaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Yokoe","sequence":"additional","affiliation":[{"name":"Toyonaka Municipal Hospital, Toyonaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Nagai","sequence":"additional","affiliation":[{"name":"Department of Neurology, Kindai University Faculty of Medicine, Osakasayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Mochizuki","sequence":"additional","affiliation":[{"name":"Department of Neurology, The University of Osaka Graduate School of Medicine, Suita, Japan"},{"name":"National Hospital Organization Osaka Toneyama Medical Center, Toyonaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,12,24]]},"reference":[{"key":"2026010703483823000_15.12.e112318.1","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-080952","article-title":"Projections for prevalence of Parkinson\u2019s disease and its driving factors in 195 countries and territories to 2050: modelling study of Global Burden of Disease Study 2021","volume":"388","author":"Su","year":"2025","journal-title":"BMJ"},{"key":"2026010703483823000_15.12.e112318.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61393-3"},{"key":"2026010703483823000_15.12.e112318.3","doi-asserted-by":"crossref","first-page":"899","DOI":"10.3233\/JPD-240272","article-title":"Parkinson\u2019s Disease Drug Therapies in the Clinical Trial Pipeline: 2024 Update","volume":"14","author":"McFarthing","year":"2024","journal-title":"J Parkinsons Dis"},{"key":"2026010703483823000_15.12.e112318.4","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/d41586-024-03074-1","article-title":"Why do obesity drugs seem to treat so many other ailments?","volume":"633","author":"Lenharo","year":"2024","journal-title":"Nature New Biol"},{"key":"2026010703483823000_15.12.e112318.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2023.12.007"},{"key":"2026010703483823000_15.12.e112318.6","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0051-5"},{"key":"2026010703483823000_15.12.e112318.7","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-022-01792-4"},{"key":"2026010703483823000_15.12.e112318.8","article-title":"The effect of GLP-1 receptor agonists in pre-clinical rodent models of Parkinson\u2019s disease: A systematic review and meta-analysis","volume":"6","author":"Dahiya","year":"2022","journal-title":"Clin Park Relat Disord"},{"key":"2026010703483823000_15.12.e112318.9","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaa262"},{"key":"2026010703483823000_15.12.e112318.10","doi-asserted-by":"crossref","DOI":"10.1186\/s13098-025-01888-1","article-title":"GLP-1 receptor agonists in Parkinson\u2019s disease: an updated comprehensive systematic review with meta-analysis","volume":"17","author":"Helal","year":"2025","journal-title":"Diabetol Metab Syndr"},{"key":"2026010703483823000_15.12.e112318.11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31585-4"},{"key":"2026010703483823000_15.12.e112318.12","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0140-6736(24)02808-3","article-title":"Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson\u2019s disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial","volume":"405","author":"Vijiaratnam","year":"2025","journal-title":"Lancet"},{"key":"2026010703483823000_15.12.e112318.13","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00378-2"},{"key":"2026010703483823000_15.12.e112318.14","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2312323"},{"key":"2026010703483823000_15.12.e112318.15","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.133429","article-title":"Semaglutide lowers body weight in rodents via distributed neural pathways","volume":"5","author":"Gabery","year":"2020","journal-title":"JCI Insight"},{"key":"2026010703483823000_15.12.e112318.16","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.4103\/NRR.NRR-D-23-01770","article-title":"Role of metabolic dysfunction and inflammation along the liver-brain axis in animal models with obesity-induced neurodegeneration","volume":"20","author":"Asimakidou","year":"2025","journal-title":"Neural Regen Res"},{"key":"2026010703483823000_15.12.e112318.17","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-022-01585-7","article-title":"Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials","volume":"21","author":"Mosenzon","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"2026010703483823000_15.12.e112318.18","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14313"},{"key":"2026010703483823000_15.12.e112318.19","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-3-201302050-00583"},{"key":"2026010703483823000_15.12.e112318.20","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21198"},{"key":"2026010703483823000_15.12.e112318.21","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22340"},{"key":"2026010703483823000_15.12.e112318.22","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S2213-8587(20)30075-9","article-title":"Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2\/3a, randomised, controlled trial","volume":"8","author":"Yamada","year":"2020","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-112318","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T11:52:15Z","timestamp":1767786735000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-112318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":22,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12,24]]},"published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1136\/bmjopen-2025-112318"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-112318","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1136\/bmjopen-2025-112318.supp1","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1136\/bmjopen-2025-112318.supp2","asserted-by":"subject"}]},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]}}}